Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EMVS

- PMLiVE

First Humira biosimilars reach EU market

World's biggest selling medicine to lose billions in sales

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

EU flag

UK pharma cheers EU science announcement

UK won't be excluded from Horizon research collaboration

- PMLiVE

Europe’s public-private alliance targets pain management

Innovative Medicines Initiative (IMI) brings pharma together with academia and patient groups in underserved area

- PMLiVE

Pharma sees European generics export plan as anti-innovation

EFPIA condemns plans - but European Commission says changes would create jobs in Europe

- PMLiVE

EU’s first health report card – must do better

Report implies Europe must shift its focus to disease prevention

- PMLiVE

Patently unclear?

The challenge of protecting  biotech innovations

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

EU flag

Europe’s cancer drug regulation is ‘broken’, claims study

Suggests EMA oncology approvals could lead to wasted funds and patient harm

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

Macron, Merkel and May: implications of the 2017 elections for the life science industry

Political instability and policy continuity in Europe’s biggest economies mean a worsening commercial environment stacked with uncertainty

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links